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Sexually transmitted infections (STIs) carry a significant
medical, economic, societal and emotional burden, although
this has been poorly characterized. Inexplicably, the fight to
eradicate congenital syphilis (CS) has failed to attract inter-
national attention,1 compared to HIV and other STIs. The
magnitude of the burden of CS globally rivals that of HIV
infection in neonates, but the disease receives little atten-
tion, even in those countries in which the seroprevalence of
CS is higher than that of HIV. Fortunately, benzathine peni-
cillin G remains an effective treatment for syphilis.2
Herein, we analyze trends in HIV and syphilis prevalence
among antenatal women in Aragua state, central Venezuela.
State regional health office data on antenatal HIVand syphilis
testing from 2000 to 2005 were reviewed. A total of 140 336
(66.4%) out of an estimated 211 474 pregnant women attend-
ing antenatal clinics in 18 municipal sanitary districts were
analyzed. This population belongs to the lowest socio-eco-
nomic level and comes from different geographical areas of
Aragua state (5500 km2 and 1 665 247 population).
During 2000 to 2005, serum samples were obtained for a
total of 148 554 HIV and 201 028 Venereal Disease Research
Laboratory (VDRL) tests (some women were tested multiple
times). HIV and VDRL testing was done using standard meth-
ods (with national quality control tests at the National
Reference Laboratory and with molecular biology techni-
ques used for the diagnosis of positive controls tested against
regionally used HIV/VDRL tests). Quantitative VDRL testing
was performed for positive samples. Thus, a positive VDRL
was considered to indicate syphilis. HIV was tested with
ELISA and confirmed with Western blot. If syphilis is serolo-
gically diagnosed, in the absence of symptoms, three doses
one week apart were given of benzathine penicillin G, 2.4
million units intramuscularly. If syphilis was diagnosed at
more than 20 weeks gestation, ultrasonography should be
performed to test for fetal syphilis. In the case of HIV, each
patient is individually assessed, but would be offered zido-
vudine as antiretroviral prophylaxis. In Venezuela, all
women attending antenatal care are recommended to§ This work was previously presented in part at the XVIth Interna-
tional AIDS Conference — AIDS 2006, Toronto, Canada, August 2006
(Abstract Number CDE0247).
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doi:10.1016/j.ijid.2008.08.012undergo different antenatal tests, including VDRL and HIV
testing, and usually more than 65% of women are covered by
those tests. Linear regressions were used to study trends
over time.
Of the samples obtained during the review period, 1621
(0.81%, 1.16% of the evaluated pregnant women) were VDRL
reactive (mean of 270 per year, 0.81%) (range of titers from
1:2 to 1:64 dilutions) and 710 (0.5%, 0.51% of the evaluated
pregnant women) were HIV reactive (mean of 118 per year,
0.7%). The data are shown in detail in Table 1. Overall, the
prevalence of syphilis among pregnant women did not change
significantly ( p = 0.189), from 1.19% in 2000 to 1.44% in 2005,
although the number of VDRL tests carried out increased
significantly ( p = 0.0395) (Table 1). The largest change
occurred in 2002 (from 0.85% to 0.79%). Overall, the pre-
valence of HIV infection among pregnant women increased,
from 0.41% in 2000 to 3.05% in 2005, although this change is
not statistically significant ( p = 0.160), in part because of the
steady increase until 2004. The significant increase that
occurred in 2004 (from 0.53% to 3.05%, Table 1) is not related
to better availability of tests or to higher coverage in their
use among pregnant women. As seen in Table 1, there was a
reduction in the number of evaluated pregnant women that
year, perhaps biasing the results compared to previous years.
Apparently the pregnant women evaluated that year corre-
sponded to a more urban, higher risk, population. There is no
HIV epidemic in the region and the increase for the period
including 2004 was not statistically significant ( p > 0.05). In
any case, these trends require further evaluation in the
future.
The overall VDRL prevalence of 0.81% in this study is
comparable to others. For example, a study carried out in
Nigeria reported a prevalence of 1.3% (n = 11 428)3 and a
study in India analyzing the same years as ours reported a
prevalence of 1.8% (n = 40 511)4. Recent studies in Brazil5 and
Nicaragua6 reported prevalences similar to ours: 0.8%
(n = 32 512) and 1.5% (n = 1059), respectively. For HIV, the
overall prevalence of 0.7% in our study is comparable to, but
higher than, that found in the Brazil (0.2%; n = 32 512)5 and
Nicaragua (0.0%; n = 1059)6 studies. The main difference
between these studies and our own in evaluating HIV infec-
tion and syphilis prevalence is that our analysis was based on
a larger study population (140 336 pregnant women).
During the past decade, the incidence of syphilis and other
STIs has increased worldwide and is comparable to the AIDS
pandemic.7 These STIs increasingly affect particular riskPublished by Elsevier Ltd. All rights reserved.
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e190 Letter to the Editorgroups, (e.g. pregnant women and neonates)1,7,8. Given this,
the World Health Organization has proposed the ‘Strategy for
the Global Elimination of CS’, the aim of which is to address
this under-recognized health problem.1,7
Although the syphilis prevalence found in this study is
low, we support the importance of such strategies and the
continued screening of pregnant women, as this will help
eliminate the adverse effects of undiagnosed and untreated
syphilis.8 Syphilis confirmation tests are not always avail-
able in countries such as Venezuela, which, coupled with
the inability of some women to afford both VDRL and other
tests, leaves the disease undetected and untreated; we
support testing and treating syphilis, as has been recom-
mended previously.3 Such a policy should ensure that no
cases are missed, especially as the drugs used to treat
syphilis are considered safe in pregnancy. It might also
result in a further decline in syphilis prevalence. Treatment
for syphilis has been benzathine penicillin G. A Cochrane
review concluded that, although penicillin is effective for
the treatment of syphilis in pregnancy and the prevention
of CS, the optimal treatment regimen is uncertain.2,9 (The
Center for Disease Control recommends benzathine peni-
cillin G, 2.4 million units intramuscularly,2 the same scheme
used in Venezuela.) In the case of HIV, preventive strategies
should be enhanced given the possible increase that was
seen in 2005.
Despite national policies on antenatal testing, syphilis
screening is still implemented only sporadically in many
countries, leaving the disease undetected and untreated
among many pregnant women. Even with wide coverage of
antenatal care, its quality must be under constant surveil-
lance. Poor organization of services and the cost of screen-
ing are the principal obstacles facing programs.7 Aspects
such as the impact of decentralization on antenatal syphilis
screening programs, on-site testing, use of health informa-
tion systems and immediate treatment that can reduce CS
case numbers should be addressed. Antenatal syphilis
screening and treatment programs are as cost effective
as many existing public health programs. This needs to
be reinforced, even in areas of low prevalence, to avoid
the unnecessary burden of STIs in pregnant women and
children.
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